Literature DB >> 16142740

Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation.

David T Felson1, Steven R Cummings.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16142740     DOI： 10.1002/art.21364

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  39 in total

1.  Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation.

Authors:  Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Allison C Stover; Janet R Abrams
Journal:  J Cancer Surviv       Date:  2010-05-08       Impact factor: 4.442

2.  The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.

Authors:  Victoria K Shanmugam; James McCloskey; Beth Elston; Sandra J Allison; Jennifer Eng-Wong
Journal:  Breast Cancer Res Treat       Date:  2011-11-11       Impact factor: 4.872

3.  Will steroidal aromatase inhibitors induce rheumatoid arthritis?

Authors:  Benoit Morel; Hubert Marotte; Pierre Miossec
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

4.  Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.

Authors:  Monica Milani; Gautam Jha; David A Potter
Journal:  Clin Med Ther       Date:  2009-03-31

5.  A prospective study of aromatase inhibitor therapy initiation and self-reported side effects.

Authors:  Lisa Gallicchio; Carla Calhoun; Kathy Helzlsouer
Journal:  Support Care Cancer       Date:  2017-03-24       Impact factor: 3.603

6.  A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.

Authors:  Jun J Mao; Sharon X Xie; John T Farrar; Carrie T Stricker; Marjorie A Bowman; Deborah Bruner; Angela DeMichele
Journal:  Eur J Cancer       Date:  2013-10-24       Impact factor: 9.162

7.  Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.

Authors:  Kelley M Kidwell; Steven E Harte; Daniel F Hayes; Anna Maria Storniolo; Janet Carpenter; David A Flockhart; Vered Stearns; Daniel J Clauw; David A Williams; N Lynn Henry
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

8.  Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.

Authors:  Jun J Mao; Carrie Stricker; Deborah Bruner; Sharon Xie; Marjorie A Bowman; John T Farrar; Brandon T Greene; Angela DeMichele
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

9.  Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Authors:  Jason D Robarge; Zereunesay Desta; Anne T Nguyen; Lang Li; Daniel Hertz; James M Rae; Daniel F Hayes; Anna M Storniolo; Vered Stearns; David A Flockhart; Todd C Skaar; N Lynn Henry
Journal:  Breast Cancer Res Treat       Date:  2016-12-09       Impact factor: 4.872

10.  Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.

Authors:  N Lynn Henry; Anna Conlon; Kelley M Kidwell; Kent Griffith; Jeffrey B Smerage; Anne F Schott; Daniel F Hayes; David A Williams; Daniel J Clauw; Steven E Harte
Journal:  J Pain       Date:  2014-01-22       Impact factor: 5.820
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.